Wealthfront Advisers’s Pacific Biosciences PACB Stock Holding History

Wealthfront Advisers’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.4K	Buy	39,511 +65	+0.2%	+$95	﹤0.01%	1105
2026 Q1	$52.1K	Buy	39,446 +1,405	+4%	+$2.51K	﹤0.01%	1062
2025 Q4	$71.1K	Sell	38,041 -52,164	-58%	-$100K	﹤0.01%	1043
2025 Q3	$115K	Buy	90,205 +387	+0.4%	+$524	﹤0.01%	992
2025 Q2	$111K	Buy	89,818 +242	+0.3%	+$279	﹤0.01%	950
2025 Q1	$106K	Buy	89,576 +51,825	+137%	+$79.5K	﹤0.01%	923
2024 Q4	$69.1K	Sell	37,751 -3,805	-9%	-$7.43K	﹤0.01%	905
2024 Q3	$70.6K	Buy	41,556 +13,836	+50%	+$22.7K	﹤0.01%	903
2024 Q2	$38K	Buy	+27,720	New	+$56K	﹤0.01%	866

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wealthfront Advisers's PACB Position: Q2 2026 in Review

Wealthfront Advisers increased its Pacific Biosciences (PACB) stake by 0.16% in Q2 2026, buying an estimated $95 and bringing the position to 39,511 shares worth $66.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1105.

Wealthfront Advisers first reported a position in PACB in Q2 2024 and has held it in 9 quarters since. The position peaked at $115K in Q3 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Wealthfront Advisers held 39,511 shares of Pacific Biosciences worth $66.4K as of Q2 2026.
Wealthfront Advisers bought 65 Pacific Biosciences shares in Q2 2026, an estimated $95.
Pacific Biosciences made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #1105 holding.
Wealthfront Advisers first reported a position in Pacific Biosciences in Q2 2024 and has held it in 9 quarters since.
Wealthfront Advisers's Pacific Biosciences position peaked at $115K in Q3 2025.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.